ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS. RETROSPECTIVE STUDY OF 92 CASES.

Ioana Ionita, Liviu Cheveresan, Maria Iordache, Maria Cheveresan, Claudiu Ionita, Despina Calamar, Mihai Ionita, Dacian Oros, Violeta Todorescu, Hortensia Ionita

Hematology, University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania

Background. The management of old patients with acute myeloid leukemia remains controversial, specially in those cases affecting very old patients (aged >=70) in which the dilemma therapeutic abstention versus treatment (with low or high intensity schemes) is a major subject.

Aims. We present the experience in our centre with this group of patients in the period 1990-2011. **Methods.** During the period of study 92 cases were diagnosed (relapses, FAB M3 cases and patients initially treated with 5-AZA were excluded). Patients were divided into 3 groups according to the treatment: no treatment (supportive treatment), low intensity treatment (low doses Ara-C: 10 mg/m²/12h s. c. days 1-21) and high intensity treatment (adapted ICE: Idarubicin 10 mg/m² days 1 and 3; Ara-C 100 mg/m²/12h days 1-3; Etoposide 100 mg/m² days 1-3).

Results. The mean age of patients was 73.2 years (60-85); sex distribution was 50 males and 42 females; mean Karnofsky index was 70; 52 patients received treatment and 40 only did not; overall survival was 6.1 months (median 2.3) significant differences were observed in the mean overall survival between the treated and notreated groups (8.2 vs 2,1 months respectively; p=0,016). In the low intensity group (27 patients) an overall response of 31% (5 CR, 6 PR, 9 NR and 7 not evaluable) was observed while in the high intensity one (25 patients) overall response was 52% (10 CR, 4 PR, 5 NR and 6 not evaluable); no statistical differences were observed between both groups considering all subgroups of response (p=0,15). Considering overall survival, no statistical differences were observed between the low and high intensity groups 7,1 vs 13,4 months (p=0.21) respectively.

Conclusions. Overall survival in the treated group is higher than in the non-treated one, differences reached statistical significance. Comparing both arms of treatment no statistical differences were observed in the quality of response, though a higher proportion of complete responses were observed in the high intensity group. No statistical differences have been observed in the overall survival between both groups of treatment.